Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug stop diabetes before it starts in transplant patients?

NCT ID NCT06913023

Prevention Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

Researchers are testing whether semaglutide, a drug used for diabetes and weight loss, can prevent post-transplant diabetes in kidney transplant recipients. The trial enrolls 37 adults who are 4 to 12 weeks past transplant and at risk for diabetes. Participants receive weekly semaglutide injections for 24 weeks, and researchers measure blood sugar after a glucose drink to see if the drug improves sugar handling. They also track side effects to assess safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide, a GLP-1 receptor agonist drug given as a weekly injection
What this could lead to
If it works, semaglutide could become a way to prevent diabetes in kidney transplant recipients, a group at high risk for the condition.
What could go wrong
This is a small, early-phase trial of 37 people, so results may not hold in larger groups. Semaglutide can cause gastrointestinal side effects, and its safety in transplant patients on multiple medications is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 37 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed and dated written informed consent. 2. Adult (≥18 years) recipients of a living or deceased donor kidney transplant 3. Between 4- and 12-weeks post kidney transplant 4. Stable kidney function defined as an eGFR \> 30 ml/min/1.73m2 (CKD-EPI) 5. At risk for PTDM at the time of transplant based on the following criteria: 1. BMI ≥ 25 kg/m2, or 2. Fasting plasma glucose 6.1-6.9 mmol/L (impaired fasting glucose), or 3. 2hr OGTT plasma glucose 7.8-11.0 (impaired glucose tolerance), or 4. HbA1C 5.5-6.4% (at risk for DM or prediabetes). Exclusion Criteria: 1. Established diagnosis of type 1 or type 2 DM as per Diabetes Canada (including the need for glucose-lowering therapy for hyperglycemia at the time of screening) 2. Kidney-Pancreas transplant recipient 3. Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening 4. History of pancreatitis 5. Personal or family history of medullary thyroid cancer or MEN2B 6. Women who are pregnant, nursing or plan on becoming pregnant whilst in the trial 7. Use of GLP1RA in the 30 days prior to screening 8. Contraindication to MRI (applicable only to those undergoing the optional MRI assessments) 9. With known or suspected hypersensitivity to semaglutide or related products 10. Patient not able to understand and comply with study requirements, based on Investigator's judgment. 11. Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcom 12. History of glucose-galactose malabsorption syndrome

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney transplant recipient are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplant recipient

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • St. Paul's Hospital

    Vancouver, British Columbia, V6Z 1Y6, Canada

  • Toronto General Hospital

    Toronto, Ontario, M5G 2N2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.